TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01358539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain education
Description: Patients receiving pain education
Study: NCT04995757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent Retriever
Description: Stent Retriever for acute ischemic stroke

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent Retriever
Description: Stent Retriever for acute ischemic stroke
Study: NCT02104765

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously.
Study: NCT00311363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn (XP13512)
Description: 1200 mg GEn (XP13512) orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEn (XP13512)
Description: 1200 mg GEn (XP13512), orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
Study: NCT02678442

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fine Needle Biopsy (FNB)
Description: The Shark Core FNB is an FDA approved device for sampling of submucosal lesions, mediastinal masses, lymph nodes and intraperitoneal masses. FNB will be performed by 22 gauge for pancreas head and by 19 gauge for all the other sites.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fine Needle Biopsy (FNB)
Description: The Shark Core FNB is an FDA approved device for sampling of submucosal lesions, mediastinal masses, lymph nodes and intraperitoneal masses. FNB will be performed by 22 gauge for pancreas head and by 19 gauge for all the other sites.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fine Needle Aspiration (FNA)
Description: Fine needle aspiration is a type of biopsy procedure. In fine needle aspiration, a thin needle is inserted into an area of abnormal-appearing tissue or body fluid, and histological material is obtained. FNA will be performed with a standard 25g needle in the usual fashion using back and forth passes for 30 seconds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fine Needle Aspiration (FNA)
Description: Fine needle aspiration is a type of biopsy procedure. In fine needle aspiration, a thin needle is inserted into an area of abnormal-appearing tissue or body fluid, and histological material is obtained. FNA will be performed with a standard 25g needle in the usual fashion using back and forth passes for 30 seconds.
Study: NCT00311363

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, orally, once daily for 12 weeks following single blind 24-week phase
Study: NCT00396084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gatifloxacin
Description: Gatifloxacin 400 mg/day x 7 days.
Study: NCT01616121

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual treatment of patients with developing acute heart failure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Impedance-Guided Therapy
Description: Non-invasive lung impedance monitor (RSMM Company, Tel Aviv, Israel)
Study: NCT00396084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Isoniazid 300 mg/day x 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin 1000 mg/day x 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Linezolid 600 mg/day x 7 days; Linezolid 600 mg every 12 hours x 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Linezolid 600 mg/day x 7 days; Linezolid 600 mg every 12 hours x 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin 400 mg/day x 7 days.
Study: NCT01568073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: 5, 25 and 50 mg of BIA 9-1067 (once-daily)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entacapone
Description: 200 mg entacapone (concomitantly with each L-dopa/DDCI dose)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa
Study: NCT01497626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib and bortezomib
Description: Lapatinib will be taken orally continuously for 28 days of each 28-day cycle, including a run-in of lapatinib alone day -7 to day 1 of cycle 1.~Bortezomib will be administered IV on days 1, 8, and 15 of each cycle. The exact doses of both drugs will be dependent on which cohort the subject is in and adverse events observed in previous cohorts.
Study: NCT01090999

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: long-term maintenance respiratory rehabilitation program
Description: To determine whether a long-term maintenance program after respiratory rehabilitation (group active comparator), in contrast to the usual minimal maintenance therapy (group no intervention), improves the cost-effectiveness through: a.- maintaining long term effects in terms of effort capacity, HRQL, and reduced exacerbations b.- reducing the total cost of care to patients, largely through reduction of exacerbations.
Study: NCT04441099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBE-002
Description: NBE-002 will be given intravenously on Day 1 of repeated 28-day cycles.
Study: NCT01568073

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levodopa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: DOPA decarboxylase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbidopa
Description: DOPA decarboxylase inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carbidopa
Description: DOPA decarboxylase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benserazide
Description: DOPA decarboxylase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benserazide
Description: DOPA decarboxylase inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Benserazide
Description: DOPA decarboxylase inhibitor
Study: NCT04441099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBE-002
Description: NBE-002 will be given intravenously on Day 1 of repeated 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBE-002
Description: NBE-002 will be given intravenously on Day 1 of repeated 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBE-002
Description: NBE-002 will be given intravenously on Day 1 of repeated 28-day cycles.
Study: NCT02253602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: maximum rate of administration 1 ml/sec

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: maximum rate of administration 1 ml/sec

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: maximum rate of administration 1 ml/sec
Study: NCT01477879

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Versabase gel with sarracenia purpurea 20% liquid extract
Description: Topical application of gel/plant mix to lesions
Study: NCT04529226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Start treatment with 12.5 mg every 12 hours with the recommendation to increase dosage by 25-50 mg/day provided it is well tolerated up to a level of 300-450 mg/day at the end of the second week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidol, pimozide, olanzapine, risperidone, amisulpride
Description: Treatment as usual using first-generation or second-generation antipsychotics
Study: NCT01834781

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed electromagnetic fields

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: w/o pulsed electromagnetic fields
Study: NCT01283815

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Description: Laparoscopic appendectomy and laparoscopic drainage of the abscess. If appendectomy is not possible due to technical difficulties only laparoscopic drainage is performed. Patients are treated with the same antimicrobial therapy as the control group (intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conservative management with percutaneous drainage
Description: Patients are treated with intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day. If the abscess is at least 3 cm in diameter percutaneous ultrasound guided drainage is performed.
Study: NCT03966391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-faceted knowledge translation intervention
Description: The intervention consists of education of relevant stakeholders of best practices and integration of best practices into the vaccination delivery program
Study: NCT01477879

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo (versabase gel only)
Description: versabase gel only
Study: NCT00707135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Rapamycin given once weekly in escalating doses. Higher dose levels will be split with the half the dose given on day 1 and half the dose on day 2 (24 hours later).
Study: NCT00630786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Administered by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conatumumab
Description: Administered by intravenous infusion
Study: NCT04567043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MORE+JITAI
Description: Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse. JITAI involves stress-triggered reminders to practice mindfulness skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supporive Psychotherapy
Description: A supportive psychotherapy group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
Study: NCT00386516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CT-01
Description: GM-CT-01 at 280 mg/m2 given IV for 4 consecutive days in 28 days cycle until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU given IV by infusion for 30, at 600 mg/m2 in combination with GM-CT-01 for 4 consecutive days in 28 days cycle until disease progression
Study: NCT03038217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine +/- Oxaliplatin
Description: Patients in ACT group will undergo postoperative adjuvant chemotherapy with single agent Capecitabine regimen or combined Capecitabine +Oxaliplatin regimen.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local resection
Description: Patients in the LR group will undergo local resection of the T1-2N0 rectal carcinoma

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical resection
Description: Patients in the RR group will undergo radical resection of the T1-2N0 rectal carcinoma

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No adjuvant chemotherapy
Description: Patients in Non-ACT group will not undergo postoperative adjuvant chemotherapy.
Study: NCT00971906

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent A/H1N1 influenza vaccine
Description: This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen \& adjuvant,or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent A/H1N1 influenza vaccine
Description: This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen \& adjuvant,or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent A/H1N1 influenza vaccine
Description: This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen \& adjuvant,or high dose of antigen \& adjuvant, or high dose of antigen, according to the study groups
Study: NCT04564196

Intervention type: PROCEDURE
Intervention: Breath Sample
Description: breathe 2 tidal volume breaths into a single breath collection bag. The breath collection bag will be closed between each breath. The combined 2 tidal volume breaths will count as a single sample.

Intervention type: PROCEDURE
Intervention: Breath Sample
Description: breathe 2 tidal volume breaths into a single breath collection bag. The breath collection bag will be closed between each breath. The combined 2 tidal volume breaths will count as a single sample.
Study: NCT02997280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Oral Tablet
Description: Dose reduction criteria for acute GVHD: grade 4 neutropenia or grade 4 thrombocytopenia related to ruxolitinib administration based on the decision of attending physician.~Dose reduction criteria for chronic GVHD: grade 3 neutropenia, grade 3 thrombocytopenia or anemia requiring transfusion, related to ruxolitinib administration based on the decision of attending physician.~Reduced dose schedule: 5 mg bid for adults and children with body weight \> 40 kg, 0.08 mg/kg bid for children with body weight \< 40 kg.~Treatment discontinuation criteria: complete response; absence of response after 28 days or progressive disease after 7 days for acute GVHD; absence of response after 84 days or progressive disease after 28 days for chronic GVHD; life-threatening complications.
Study: NCT03316521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMY-101
Description: AMY-101 is a selective inhibitor of complement activation, which binds to the complement component C3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMY-101
Description: AMY-101 is a selective inhibitor of complement activation, which binds to the complement component C3.
Study: NCT02261467

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo (normal saline) injected into the protocol-specified areas on Day 1.
Study: NCT01658579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HOE901-U300 (new formulation of insulin glargine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HOE901-U300 (new formulation of insulin glargine)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus (insulin glargine)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lantus (insulin glargine)
Study: NCT01908959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Madres para la Salud
Description: Participants attended Madres para la Salud sessions in a group, led by a promotora at the Maricopa Medical Center and other community based sites. Sessions consisted of a 30 minute education and social support session where women learned to walk at least 150 minutes a week at a 20 minute-mile pace, and up to 30 minutes of moderate intensity walking with the group. Participants received a pedometer and learned to monitor their walking intensity. Participants set and reviewed weekly walking goals at the group sessions and recorded aerobic steps per day. After the 12 week sessions, participants met with the promotora once a week for 40 weeks of in-group walking at a moderate intensity for 30 minutes, to download and review pedometer data. Data was collected at baseline, 3, 6, 9 and 12 months.
Study: NCT01410266

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Alternative follow-up
Description: Alternative follow-up consists of a self-administered semi-quantitative pregnancy test designed to measure urine beta-hCG levels, and a self-administered questionnaire consisting of 7 questions. Results of both are reviewed by the provider to determine if in-clinic follow-up is needed.
Study: NCT03702530

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3x 50 L3 larvae immunisation with albendazole treatment
Description: Immunisation with 50 Necator americanus L3 larvae at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 3x placebo immunisation with albendazole treatment
Description: Mock immunisation with water at week 0, 3 and 6 with albendazole treatment at week 2, 5 and 8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2x 50 L3 larvae infection
Description: After (mock) immunisation, infection with 50 Necator americanus larvae at week 13 and 15
Study: NCT03833154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg every 4 weeks \[q4w\] intravenously \[iv\] for up to 26 cycles or until progression or other discontinuation criteria are met.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for infusion every 4 weeks iv for up to 26 cycles or until progression or other discontinuation criteria are met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (Osimertinib cohort, single-arm, open-label separate cohort)
Description: Osimertinib 80 mg every day \[qd\] orally for up to 36 months or until progression or other discontinuation criteria are met. Osimertinib treatment should start from 7 to 14 days after completion of SBRT
Study: NCT02414204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Sildenafil, a phosphodiesterase 5 inhibitor that enhances the effects of nitric oxide (NO), has been shown in experimental and clinical studies in cardiovascular disease to improve endothelial function and decrease vascular stenosis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be over encapsulated to identical to drug comparison
Study: NCT03302819

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MARIA scan
Description: The patient will have an additional MARIA scan along with conventional imaging, pathology and surgical procedures.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MARIA scan
Description: The patient will have an additional MARIA scan along with conventional imaging, pathology and surgical procedures.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MARIA scan
Description: The patient will have an additional MARIA scan along with conventional imaging, pathology and surgical procedures.
Study: NCT04100148

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SyncAV programmed ON
Description: For those subjects randomized to SyncAV programmed ON, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF), at BiV pacing nominal settings, with various SyncAV programmed offsets, and at LV first 30 ms, RV first 30 ms and LV-only pacing with optimal SyncAV offsets. The site will then program the subject's device using the SyncAV offset that provided the narrowest QRS duration.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed AV delay
Description: For those subjects randomized to the fixed AV delay arm, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF) and at BiV pacing nominal settings. Sites will then program the subject's device using BiV pacing nominal settings.
Study: NCT01716858

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sulforaphane-rich Broccoli Sprout Extract
Study: NCT01326039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: perineural bupivacaine 5 mg/ml 20 ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: perineural isotonic saline 20 ml
Study: NCT01703923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT00172185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teduglutide 0.05 mg/kg/d
Description: 0.05 mg/kg/d subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teduglutide 0.10 mg/kg/d
Description: 0.10 mg/kg/d subcutaneous injection
Study: NCT05892055

Intervention type: OTHER
Intervention: Procedure
Description: All children will receive a functional magnetic resonance imaging (fMRI) scan, where they will complete some preliminary scans while completing two cognitive tasks, and then be removed from the scanner to complete a water loading symptom provocation task (WL-SPT). After the WL-SPT task, they will resume the fMRI scan and complete additional cognitive tasks to assess for diminished attentional regulation. Measures of pain intensity, pain unpleasantness, and state anxiety will be obtained throughout.

Intervention type: OTHER
Intervention: Procedure
Description: All children will receive a functional magnetic resonance imaging (fMRI) scan, where they will complete some preliminary scans while completing two cognitive tasks, and then be removed from the scanner to complete a water loading symptom provocation task (WL-SPT). After the WL-SPT task, they will resume the fMRI scan and complete additional cognitive tasks to assess for diminished attentional regulation. Measures of pain intensity, pain unpleasantness, and state anxiety will be obtained throughout.
Study: NCT02749968

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: 1 mL of liposomal bupivacaine injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: 1 mL of 0.9% saline injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
Study: NCT00982098

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BioFeedback; Functional Electrical Stimulation; Pelvic Floor Muscle training exercises
Description: After surgery: physical therapist's assisted pelvic floor muscle biofeedback (15 min/day for 10 days), followed by patient's instruction for pelvic floor muscle training and home based exercised pelvic floor muscle for 10 days. Then pelvic floor muscle biofeedback (15 min/day for 10 days) and functional electrical stimulation of pelvic floor (30 min/day for 10 days).